Human Metabolome Technologies, Inc.
6090.T · JPX
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.95 | -1.02 | 2.34 | 0.04 |
| FCF Yield | 5.00% | 5.46% | 3.80% | 4.13% |
| EV / EBITDA | 8.63 | 6.14 | 9.36 | 9.23 |
| Quality | ||||
| ROIC | 11.66% | 9.36% | 10.49% | 11.03% |
| Gross Margin | 63.37% | 64.60% | 66.17% | 68.67% |
| Cash Conversion Ratio | 1.46 | 0.90 | 1.00 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.85% | 3.23% | 4.95% | 3.03% |
| Free Cash Flow Growth | 11.00% | 20.58% | -5.51% | 386.78% |
| Safety | ||||
| Net Debt / EBITDA | -4.11 | -4.46 | -4.47 | -3.86 |
| Interest Coverage | 99.88 | 105.09 | 93.15 | 86.34 |
| Efficiency | ||||
| Inventory Turnover | 10.45 | 12.88 | 16.76 | 8.83 |
| Cash Conversion Cycle | 75.18 | 78.71 | 58.25 | 88.39 |